Valuation: Cyclacel Pharmaceuticals Inc

Market Cap 58.28L 51.78L 48.33L 44.05L 83.08L 56Cr 83.85L 5.85Cr 2.27Cr 29Cr 2.19Cr 2.14Cr 92Cr P/E 2024
-0.18x
P/E 2025 -0.23x
Enterprise Value 23.43L 20.82L 19.43L 17.71L 33.4L 23Cr 33.71L 2.35Cr 91.12L 12Cr 87.97L 86.06L 37Cr EV / Sales 2024
-1,79,78,488x
EV / Sales 2025 50,43,119x
Free-Float
64.75%
Yield 2024 *
-
Yield 2025 -
Manager TitleAgeSince
Chief Executive Officer 44 26/02/2025
Director of Finance/CFO 37 26/02/2025
Director TitleAgeSince
Director/Board Member 44 26/02/2025
Director/Board Member 37 26/02/2025
Director/Board Member 40 02/04/2025
Change 5-day change 1-year change 3-year change Capi.($)
+4.16%+3.04%+49.37%+94.17% 7.42TCr
-3.11%-3.53%+20.19%+81.44% 5.74TCr
+0.89%-0.63%+2.17%+36.19% 4.76TCr
+0.36%+0.81%+342.39%+742.40% 4.43TCr
-0.96%-4.50%+24.96%+35.38% 4.25TCr
-0.20%-0.77%+4.13%+105.50% 4.07TCr
-0.54%+2.93%+9.31%+50.41% 3.1TCr
-2.68%+2.92%+29.33%+22.72% 2.85TCr
+0.05%-1.64%-8.14%-11.37% 2.43TCr
Average -0.23%-0.59%+52.63%+128.54% 4.34TCr
Weighted average by Cap. +0.12%-0.84%+56.96%+138.26%

Financials

2024 2025
Net sales 0.04 0.04 0.04 0.03 0.06 4.13 0.06 0.43 0.17 2.11 0.16 0.16 6.78 0.75 0.66 0.62 0.56 1.06 71.81 1.07 7.5 2.9 36.71 2.8 2.74 117.82
Net income -1.12Cr -99.62L -92.98L -84.75L -1.6Cr -107.78Cr -1.61Cr -11Cr -4.36Cr -55Cr -4.21Cr -4.12Cr -176.84Cr -29.98L -26.64L -24.86L -22.66L -42.74L -29Cr -43.14L -3.01Cr -1.17Cr -15Cr -1.13Cr -1.1Cr -47Cr
Net Debt -31.37L -27.87L -26.01L -23.71L -44.72L -30Cr -45.14L -3.15Cr -1.22Cr -15Cr -1.18Cr -1.15Cr -49Cr -34.85L -30.96L -28.9L -26.34L -49.68L -34Cr -50.14L -3.5Cr -1.36Cr -17Cr -1.31Cr -1.28Cr -55Cr
Logo Cyclacel Pharmaceuticals Inc
Bio Green Med Solution, Inc., formerly Cyclacel Pharmaceuticals, Inc., is a diversified company engaged in both the fire protection and biopharmaceutical industries. It develops medicines based on cell cycle, epigenetics and mitosis biology. Its Polo-like kinase 1 (PLK1) is a serine/threonine kinase with a central role in cell division and an important regulator of the DNA damage checkpoint. PLK1 overexpression correlates with poor patient prognosis in several tumors, including esophageal, gastric, leukemia, non-small cell lung cancer, ovarian, and squamous cell cancers, as well as MYC-amplified cancers. Plogosertib is a novel, small molecule, selective and potent PLK1 inhibitor. Its Fire Safety division specializes in supplying and trading various protective and fire safety equipment to both domestic and international markets. It provides fire safety products, including fire extinguishers, foam systems, fire-resistant doors, personal protective equipment, and fire safety apparel.
Employees
-